CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review A prospective natural-history study of coronary atherosclerosis Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease: A Meta-Analysis of Randomized Trials Screening for Atrial Fibrillation With Electrocardiography US Preventive Services Task Force Recommendation Statement Incidence, Predictors, and Outcomes of In-Hospital Percutaneous Coronary Intervention Following Coronary Artery Bypass Grafting The Prognostic Value of Exercise Echocardiography After Percutaneous Coronary Intervention Better Prognosis After Complete Revascularization Using Contemporary Coronary Stents in Patients With Chronic Kidney Disease

Original Research2018 Jun;25(3):769-776.

JOURNAL:J Nucl Cardiol. Article Link

Guidelines in review: Comparison of the 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes and the 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Prejean SP, Din M, Reyes E et al. Keywords: Non-ST elevation acute coronary syndrome; coronary artery disease; non-invasive imaging; stress testing

ABSTRACT


In this Guidelines in Review, we review side-by-side the recommendations provided by the 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes and the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. We review the recommendations for imaging in the evaluation of patients with possible ACS followed by the diagnostic evaluation of patients with proven NSTE-ACS, based on their risk for adverse clinical events.